Kenvue (NYSE:KVUE) General Counsel Sells $679,751.06 in Stock

Kenvue Inc. (NYSE:KVUE) General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Kenvue Trading Down 0.1%

NYSE KVUE opened at $17.18 on Friday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $24.35. The stock has a 50-day simple moving average of $17.50 and a 200 day simple moving average of $17.32. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $32.98 billion, a PE ratio of 20.21, a P/E/G ratio of 1.30 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.24 earnings per share. Research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.8%. Kenvue’s payout ratio is currently 97.65%.

Analyst Ratings Changes

Several research firms have weighed in on KVUE. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Argus upgraded shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Citigroup dropped their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $19.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KVUE. Montag A & Associates Inc. lifted its position in Kenvue by 6.3% in the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after acquiring an additional 600 shares in the last quarter. Cornerstone Wealth Group LLC increased its holdings in Kenvue by 5.9% during the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after purchasing an additional 606 shares in the last quarter. Physician Wealth Advisors Inc. raised its stake in shares of Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. Mill Creek Capital Advisors LLC lifted its holdings in shares of Kenvue by 0.6% in the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after purchasing an additional 701 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management lifted its holdings in shares of Kenvue by 0.3% in the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after purchasing an additional 712 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.